Idogen presents the company's technology platform at a scientific congress
Idogen AB (publ) has been invited to present its technology platform for tolerogenic cell therapy at the scientific congress 5th Antigen-Specific Immune Tolerance Summit on 27 January, 2022. This annual meeting involves leading researchers in the field; ranging from American universities to representatives from both large pharmaceutical companies and innovative biotechnology companies.
Idogen develops tolerogenic cell therapies for the treatment of unwanted activation of the immune system. In 2021, the company has taken great strides forward with its most advanced development program, IDO 8, for the treatment of patients with severe hemophilia A who have developed antibodies to their vital treatment with coagulation factor VIII. The company recently submitted an application to conduct a clinical trial with IDO 8 to the Swedish Medical Products Agency and then a new application to the Norwegian Medicines Agency NoMA. The plan is - subject to approval - that the study will start during the second quarter of 2022.
Åsa Schiött, Chief Scientific Officer (CSO) at Idogen, will at the congress present the company's technical platform and development journey under the theme "A Novel Tolerogenic Dendritic Cell Platform with the Potential to Present the Antigen FVIII to Induce Tolerance Against FVIII in Hemophilia A Patients".
“We are proud of the opportunity to present our innovative technology platform at congress with many authorities in the field at this international congress. It is an important recognition of our scientific achievements and shows the great interest in using the opportunity to create antigen-specific tolerance in the treatment of a number of serious conditions and diseases ", says Åsa Schiött, CSO at Idogen.
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Phone: +46 70 918 00 10
Email: anders.karlsson@idogen.com
Certified Adviser:
Erik Penser Bank AB, Box 7405, 103 91 Stockholm
Phone: +46 (0)8-463 80 00
Email: certifiedadviser@penser.se
The information was submitted for publication, through the agency of the contact persons set out above, on 27 January 2022 at 08.46 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com